Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C; Eur J Haematol. 2020; 104(3):251-258

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou, A; Hedayati, E; Hellstrom, M; Johansson, H; Gnant, M; Steger, G; Greil, R; Untch, M; Moebus, V; Loibl, S; Foukakis, T; Bergh, J; Matikas, A Acta Oncol. 2020; 59(1):75-81

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rumpold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N Leuk Lymphoma. 2020; 61(2):377-386

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.

Brandberg, Y; Johansson, H; Hellström, M; Gnant, M; Möbus, V; Greil, R; Foukakis, T; Bergh, J; Breast Cancer Res Treat. 2020; 181(1):87-96

External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.

Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; St?ger, H; Stotz, M; Gerger, A; Pichler, M CANCER MED-US. 2020; 9(15): 5473-5479.

Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.

Bago-Horvath, Z; Rudas, M; Singer, CF; Greil, R; Balic, M; Lax, SF; Kwasny, W; Hulla, W; Gnant, M; Filipits, M CLIN CANCER RES. 2020; 26(21): 5682-5688.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M EUR J CANCER. 2020; 132: 43-52.

Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.

Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stoger, H; Stotz, M; Gerger, A; Pichler, M CANCERS. 2020; 12(5):

RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia.

Gassner, FJ; Zaborsky, N; Feldbacher, D; Greil, R; Geisberger, R CANCERS. 2020; 12(5):

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)

Gampenrieder, SP MEMO-MAG EUR MED ONC. 2020; 13(3): 253-254.